Literature DB >> 33572481

Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives.

Kristoffer Kjærgaard1, Anne Catrine Daugaard Mikkelsen1, Charlotte Wilhelmina Wernberg2, Lea Ladegaard Grønkjær2, Peter Lykke Eriksen1, Malene Flensborg Damholdt3,4, Rajeshwar Prosad Mookerjee1,5, Hendrik Vilstrup1, Mette Munk Lauridsen2, Karen Louise Thomsen1,5.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) has emerged as the hepatic component of the metabolic syndrome and now seemingly affects one-fourth of the world population. Features associated with NAFLD and the metabolic syndrome have frequently been linked to cognitive dysfunction, i.e. systemic inflammation, vascular dysfunction, and sleep apnoea. However, emerging evidence suggests that NAFLD may be a cause of cognitive dysfunction independent of these factors. NAFLD in addition exhibits dysbiosis of the gut microbiota and impaired urea cycle function, favouring systemic ammonia accumulation and further promotes systemic inflammation. Such disruption of the gut-liver-brain axis is essential in the pathogenesis of hepatic encephalopathy, the neuropsychiatric syndrome associated with progressive liver disease. Considering the growing burden of NAFLD, the morbidity from cognitive impairment is expected to have huge societal and economic impact. The present paper provides a review of the available evidence for cognitive dysfunction in NAFLD and outlines its possible mechanisms. Moreover, the clinical challenges of characterizing and diagnosing cognitive dysfunction in NAFLD are discussed.

Entities:  

Keywords:  ammonia; cognition; hepatic encephalopathy.; inflammation; neurodegeneration; neuropsychology; non-alcoholic steatohepatitis; psychometric; vascular dysfunction

Year:  2021        PMID: 33572481      PMCID: PMC7916374          DOI: 10.3390/jcm10040673

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  159 in total

1.  Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies.

Authors:  G Cheng; C Huang; H Deng; H Wang
Journal:  Intern Med J       Date:  2012-05       Impact factor: 2.048

2.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

3.  Microglia activation in hepatic encephalopathy in rats and humans.

Authors:  Irina Zemtsova; Boris Görg; Verena Keitel; Hans-Jürgen Bidmon; Karsten Schrör; Dieter Häussinger
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

4.  Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.

Authors:  John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust
Journal:  J Hepatol       Date:  2006-03-20       Impact factor: 25.083

5.  Functional impairment in alcoholic liver disease and non-alcoholic fatty liver disease is significant and persists over 3 years of follow-up.

Authors:  Chris Elliott; James Frith; Christopher P Day; David E J Jones; Julia L Newton
Journal:  Dig Dis Sci       Date:  2013-04-23       Impact factor: 3.199

6.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.

Authors:  J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark
Journal:  Neurology       Date:  1989-09       Impact factor: 9.910

7.  Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline.

Authors:  L C Silbert; C Nelson; D B Howieson; M M Moore; J A Kaye
Journal:  Neurology       Date:  2008-07-08       Impact factor: 9.910

Review 8.  Cognitive impairment in depression: a systematic review and meta-analysis.

Authors:  P L Rock; J P Roiser; W J Riedel; A D Blackwell
Journal:  Psychol Med       Date:  2013-10-29       Impact factor: 7.723

9.  Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant.

Authors:  Runping Liu; Jason D Kang; R Balfour Sartor; Masoumeh Sikaroodi; Andrew Fagan; Edith A Gavis; Huiping Zhou; Phillip B Hylemon; Jeremy W Herzog; Xiaojiaoyang Li; Robert H Lippman; Javier Gonzalez-Maeso; James B Wade; Siddhartha Ghosh; Emily Gurley; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.298

10.  Lipocalin 2 induces neuroinflammation and blood-brain barrier dysfunction through liver-brain axis in murine model of nonalcoholic steatohepatitis.

Authors:  Ayan Mondal; Dipro Bose; Punnag Saha; Sutapa Sarkar; Ratanesh Seth; Diana Kimono; Muayad Albadrani; Mitzi Nagarkatti; Prakash Nagarkatti; Saurabh Chatterjee
Journal:  J Neuroinflammation       Date:  2020-07-04       Impact factor: 8.322

View more
  7 in total

Review 1.  Fatty liver and cerebrovascular disease: plausible association and possible mechanisms.

Authors:  Sahil Khanna; Neal S Parikh; Lisa B VanWagner
Journal:  Curr Opin Lipidol       Date:  2022-02-01       Impact factor: 4.616

2.  Palm Oil-Rich Diet Affects Murine Liver Proteome and S-Palmitoylome.

Authors:  Ewelina Ziemlińska; Justyna Sobocińska; Anna Świątkowska; Aneta Hromada-Judycka; Gabriela Traczyk; Agata Malinowska; Bianka Świderska; Anna Mietelska-Porowska; Anna Ciesielska; Katarzyna Kwiatkowska
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

3.  Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy.

Authors:  María-Pilar Ballester; Juan-José Gallego; Alessandra Fiorillo; Franc Casanova-Ferrer; Carla Giménez-Garzó; Desamparados Escudero-García; Joan Tosca; María-Pilar Ríos; Cristina Montón; Lucía Durbán; José Ballester; Salvador Benlloch; Amparo Urios; Teresa San-Miguel; Elena Kosenko; Miguel-Ángel Serra; Vicente Felipo; Carmina Montoliu
Journal:  Sci Rep       Date:  2022-02-14       Impact factor: 4.379

4.  Substance-use simulation impairs driving capability in patients with cirrhosis regardless of hepatic encephalopathy.

Authors:  Chathur Acharya; Sara McGeorge; Andrew Fagan; James B Wade; Hannah Lee; Velimir Luketic; Richard K Sterling; Leroy Thacker; Jasmohan S Bajaj
Journal:  Hepatol Commun       Date:  2022-07-17

5.  The Mediation Role of the Risk of Non-Alcoholic Fatty Liver Disease in Relationship between Lutein and Zeaxanthin and Cognitive Functions among Older Adults in the United States.

Authors:  Chen Chen; Zhonghai Lu; Dongfeng Zhang; Suyun Li
Journal:  Nutrients       Date:  2022-01-28       Impact factor: 5.717

6.  Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study.

Authors:  Luisa Lampignano; Rossella Donghia; Chiara Griseta; Gianvito Lagravinese; Sabrina Sciarra; Roberta Zupo; Fabio Castellana; Ilaria Bortone; Vito Guerra; Sarah Tirelli; Sara De Nucci; Rossella Tatoli; Madia Lozupone; Giancarlo Sborgia; Antonio Leo; Giovanni De Pergola; Gianluigi Giannelli; Francesco Panza; Rodolfo Sardone
Journal:  Front Aging Neurosci       Date:  2021-12-08       Impact factor: 5.750

7.  Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall II prospective cohort study.

Authors:  Céline Ben Hassen; Aurore Fayosse; Benjamin Landré; Martina Raggi; Mikaela Bloomberg; Séverine Sabia; Archana Singh-Manoux
Journal:  BMJ       Date:  2022-02-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.